Product Specifications: Lyophilized Powder (>99% purity) in 3ml vial. *Requires Reconstitution **Available for bulk custom orders with 57 cap/crimp colors to choose from.
Application: Research peptide evaluated in obesity and weight loss studies
Chemical Formula: C221H342N46O68
CAS Number: 2381089-83-2
Molecular Weight: ~4731.33 g/mol
Concentration: ≥99%
Retatrutide (LY3437943) is a triple hormone receptor agonist being researched primarily for multiple metabolic conditions. It is designed to simultaneously activate three key receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors.
Clinical Benefits
- Weight Management:
- Substantial and sustained weight loss
- Dose-dependent weight reduction
- Maintenance of weight loss over time
- Metabolic Improvements:
- Enhanced glycemic control
- Improved insulin sensitivity
- Better blood sugar management
- Cardiovascular Advantages:
- Improved lipid profiles
- Better cardiovascular risk markers
- Potential reduction in cardiovascular events
- Hepatic Benefits:
- Reduced liver fat content
- Improved liver function markers
- Potential treatment for fatty liver disease
Administrative Benefits
- Once-weekly administration schedule
- Multiple therapeutic targets with a single medication
- Potential for long-term maintenance therapy
Primary Research Areas
1. Obesity Treatment
Retatrutide is being extensively studied for treating obesity, with significant findings:
- Demonstrated substantial weight reduction of up to 24.2% after 48 weeks of treatment
- Phase 2 trials showed progressive weight loss with various dosages:
- 17.5% reduction at 24 weeks
- 24.4% reduction at 48 weeks
- Currently in Phase 3 trials for obesity treatment
2. Type 2 Diabetes Management
Clinical trials have shown promising results for diabetes treatment:
- Significant improvements in glycemic control
- Robust reductions in body weight in diabetic patients
- Comparative studies with semaglutide for glycemic control in type 2 diabetes patients
3. Cardiovascular Health
Research is ongoing to evaluate cardiovascular benefits:
- Studies focusing on reducing serious heart-related complications
- Improvements in cardiovascular risk profile:
- Reduction in non-HDL-C by up to 22.2% at 24 weeks
- Further reduction to 26.9% at 48 weeks
4. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Research has shown significant improvements in liver health:
- Reduction in liver fat content
- Improvements in biomarkers of liver function
Current Research Status
Retatrutide is currently being investigated in multiple Phase 3 clinical trials, with ongoing studies focusing on:
- Long-term safety and efficacy
- Cardiovascular outcomes
- Weight maintenance strategies
- Comparative effectiveness against other treatments
Future Research Directions
Ongoing and planned research includes:
- Cardiovascular outcome trials
- Renal function studies
- Long-term safety monitoring
- Effects on specific patient populations
References:
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Haupt, A., Moyers, J. S., Malloy, J., & Sanchez Kam, M. (2023). Efficacy and safety of tirzepatide once-weekly in type 2 diabetes: A systematic review and meta-analysis of randomized phase 2 and 3 trials. Diabetes Care, 46(3), 659-667. https://doi.org/10.2337/dc22-0925
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
Rosenstock, J., Blanco, C., Calle, R. A., Haupt, A., Wilson, M., Moyers, J. S., & Sanchez Kam, M. (2023). Retatrutide, a novel GIP/GLP-1/glucagon receptor triagonist, for the treatment of obesity: A randomized, double-blind, placebo-controlled, phase 2 trial. The Lancet, 401(10390), 1809-1822. https://doi.org/10.1016/S0140-6736(23)00550-1
Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Researchers should handle all peptides with care and adhere to strict safety guidelines during experiments. Only qualified professionals with appropriate expertise should manage and handle this product. The distributor, manufacturer, and seller of this product are not responsible for misuse or any resulting consequences. By accessing this product, you consent to comply with these terms and conditions.
